Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 5/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649320 | 0.86 | TTR (0.44) | ELANEIDO1MALT1NQO2POLB | |
| SCHEMBL13649318 | 0.79 | CBR1 (0.47) | ELANEIDO1MALT1NQO2POLB | |
| SCHEMBL4122496 | 0.77 | MALT1 (0.57) | IDO1MALT1NQO2POLBKDM4E | |
| SCHEMBL13649337 | 0.72 | CBR1 (0.50) | ELANEIDO1MALT1NQO2LMNA | |
| SCHEMBL13649316 | 0.71 | ALDH1A1 (0.54) | ELANEIDO1POLBKDM4ELMNA | |
| SCHEMBL13814546 | 0.70 | MALT1 (0.55) | IDO1MALT1KDM4ELMNAGAA | |
| SCHEMBL4116583 | 0.70 | MALT1 (0.49) | IDO1MALT1NQO2POLBEPHX2 | |
| SCHEMBL4034335 | 0.69 | MALT1 (0.62) | IDO1MALT1NQO2GAA | |
| SCHEMBL4122244 | 0.66 | MALT1 (0.45) | MALT1AKT1 | |
| SCHEMBL13649295 | 0.66 | MALT1 (0.45) | MALT1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2009-10-01 | — | — | US | disclosed |
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | CCNA1, MKI67, CCNT1 | ELANE 1875/4885IDO1 1244/4885MALT1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.